FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1497381120> ?p ?o ?g. }

• W1497381120 endingPage "7916" @default.
• W1497381120 startingPage "7902" @default.
• W1497381120 abstract "// Jiayu Li 1 , Xuefei Li 2 , Shengxiang Ren 1 , Xiaoxia Chen 1 , Yishi Zhang 1 , Fei Zhou 1 , Mingchuan Zhao 1 , Chao Zhao 2 , Xiu Chen 3 , Ningning Cheng 1 , Yinmin Zhao 4 , Caicun Zhou 1 , Fred R. Hirsch 5 1 Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Tongji University Medical School Cancer Institute, Shanghai, China 2 Department of Lung Cancer and Immunology, Shanghai Pulmonary Hospital, Tongji University, Tongji University Medical School Cancer Institute, Shanghai, China 3 Department of Respiration, Zaozhuang Municipal Hospital, Zaozhuang, Shandong, China 4 Department of Central Laboratory, Shanghai Pulmonary Hospital, Tongji University, Shanghai, China 5 Departments of Medicine and Pathology, University of Colorado Cancer Center, Aurora, Colorado, USA. Correspondence to: Dr. Caicun Zhou, e-mail: caicunzhoudr@163.com Key Words: Non-small cell lung cancer, MiR-200c, Epidermal growth factor receptor, Wild type, Tyrosine-kinase inhibitor Received: July 05, 2014      Accepted: July 29, 2014      Published: August 08, 2014 ABSTRACT Several randomized trials have demonstrated non-small cell lung cancer (NSCLC) patients with activating epidermal growth factor receptor (EGFR) mutations can achieve favorable clinical outcomes on treatment with EGFR tyrosine kinase inhibitors (TKIs). EGFR mutation is considered as a predictive marker for efficacy of EGFR-TKIs in NSCLC. Here we show miR-200c overexpression was correlated with the epithelial phenotype and sensitivity to gefitinib in EGFR wild-type NSCLC cell lines. Up-regulated miR-200c could regain the sensitivity to gefitinib in the EGFR wild-type cell lines and miR-200c could regulate epithelial to mesenchymal transition through PI3K/AKT and MEK/ERK pathways. NSCLC patients at advanced stage (N=150) who received EGFR-TKIs (gefitinib or erlotinib) as second- or third-line therapy from September 2008 to December 2012 were included in the study. In 66 NSCLC patients with wild-type EGFR , high levels of miR-200c expression was associated with higher disease control rate (DCR), longer progression-free survival (PFS) and longer overall survival (OS) compared with low miR-200c expression subgroup. In the subgroup with EGFR mutation, the trend remained the same but not statistically significant. Overall, these findings indicated that miR-200c might be a predictive biomarker for sensitivity to EGFR-TKIs in advanced NSCLC patients with wild-type EGFR ." @default.
• W1497381120 created "2016-06-24" @default.
• W1497381120 creator A5008421599 @default.
• W1497381120 creator A5014915114 @default.
• W1497381120 creator A5016049048 @default.
• W1497381120 creator A5020376217 @default.
• W1497381120 creator A5020767316 @default.
• W1497381120 creator A5021941803 @default.
• W1497381120 creator A5030449789 @default.
• W1497381120 creator A5040311687 @default.
• W1497381120 creator A5055029433 @default.
• W1497381120 creator A5071851332 @default.
• W1497381120 creator A5072864969 @default.
• W1497381120 creator A5089167855 @default.
• W1497381120 date "2014-08-08" @default.
• W1497381120 modified "2023-10-11" @default.
• W1497381120 title "MiR-200c overexpression is associated with better efficacy of EGFR-TKIs in non-small cell lung cancer patients with EGFR wild-type" @default.
• W1497381120 cites W1513255820 @default.
• W1497381120 cites W1967738163 @default.
• W1497381120 cites W1973890143 @default.
• W1497381120 cites W1973951591 @default.
• W1497381120 cites W1974213646 @default.
• W1497381120 cites W1978442696 @default.
• W1497381120 cites W1982158259 @default.
• W1497381120 cites W1997788346 @default.
• W1497381120 cites W2006767098 @default.
• W1497381120 cites W2009851812 @default.
• W1497381120 cites W2018922262 @default.
• W1497381120 cites W2026342389 @default.
• W1497381120 cites W2028950794 @default.
• W1497381120 cites W2030864655 @default.
• W1497381120 cites W2046104645 @default.
• W1497381120 cites W2050249255 @default.
• W1497381120 cites W2055130200 @default.
• W1497381120 cites W2072470816 @default.
• W1497381120 cites W2077494872 @default.
• W1497381120 cites W2105026490 @default.
• W1497381120 cites W2116636854 @default.
• W1497381120 cites W2116719283 @default.
• W1497381120 cites W2123027432 @default.
• W1497381120 cites W2125120607 @default.
• W1497381120 cites W2127357802 @default.
• W1497381120 cites W2130488043 @default.
• W1497381120 cites W2135192471 @default.
• W1497381120 cites W2143171062 @default.
• W1497381120 cites W2145322551 @default.
• W1497381120 cites W2154331804 @default.
• W1497381120 cites W2160982674 @default.
• W1497381120 cites W2166084034 @default.
• W1497381120 doi "https://doi.org/10.18632/oncotarget.2302" @default.
• W1497381120 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4202169" @default.
• W1497381120 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25277203" @default.
• W1497381120 hasPublicationYear "2014" @default.
• W1497381120 type Work @default.
• W1497381120 sameAs 1497381120 @default.
• W1497381120 citedByCount "53" @default.
• W1497381120 countsByYear W14973811202015 @default.
• W1497381120 countsByYear W14973811202016 @default.
• W1497381120 countsByYear W14973811202017 @default.
• W1497381120 countsByYear W14973811202018 @default.
• W1497381120 countsByYear W14973811202019 @default.
• W1497381120 countsByYear W14973811202020 @default.
• W1497381120 countsByYear W14973811202022 @default.
• W1497381120 countsByYear W14973811202023 @default.
• W1497381120 crossrefType "journal-article" @default.
• W1497381120 hasAuthorship W1497381120A5008421599 @default.
• W1497381120 hasAuthorship W1497381120A5014915114 @default.
• W1497381120 hasAuthorship W1497381120A5016049048 @default.
• W1497381120 hasAuthorship W1497381120A5020376217 @default.
• W1497381120 hasAuthorship W1497381120A5020767316 @default.
• W1497381120 hasAuthorship W1497381120A5021941803 @default.
• W1497381120 hasAuthorship W1497381120A5030449789 @default.
• W1497381120 hasAuthorship W1497381120A5040311687 @default.
• W1497381120 hasAuthorship W1497381120A5055029433 @default.
• W1497381120 hasAuthorship W1497381120A5071851332 @default.
• W1497381120 hasAuthorship W1497381120A5072864969 @default.
• W1497381120 hasAuthorship W1497381120A5089167855 @default.
• W1497381120 hasBestOaLocation W14973811201 @default.
• W1497381120 hasConcept C121608353 @default.
• W1497381120 hasConcept C126322002 @default.
• W1497381120 hasConcept C143998085 @default.
• W1497381120 hasConcept C2776256026 @default.
• W1497381120 hasConcept C2779438470 @default.
• W1497381120 hasConcept C2780580887 @default.
• W1497381120 hasConcept C2781230642 @default.
• W1497381120 hasConcept C502942594 @default.
• W1497381120 hasConcept C71924100 @default.
• W1497381120 hasConceptScore W1497381120C121608353 @default.
• W1497381120 hasConceptScore W1497381120C126322002 @default.
• W1497381120 hasConceptScore W1497381120C143998085 @default.
• W1497381120 hasConceptScore W1497381120C2776256026 @default.
• W1497381120 hasConceptScore W1497381120C2779438470 @default.
• W1497381120 hasConceptScore W1497381120C2780580887 @default.
• W1497381120 hasConceptScore W1497381120C2781230642 @default.
• W1497381120 hasConceptScore W1497381120C502942594 @default.
• W1497381120 hasConceptScore W1497381120C71924100 @default.
• W1497381120 hasIssue "17" @default.
• W1497381120 hasLocation W14973811201 @default.

• next